Many women with multiple sclerosis (MS) who wish to conceive face difficult treatment decisions that may have potentially conflicting impacts on their own health and that of the fetus. While the risk of relapses decreases throughout pregnancy into the third trimester, the risk thereof increases dramatically in the first three postpartum months. 1 While some studies suggest an overall "null" or even protective effect of pregnancy on longer-term prognosis, 2 it is possible that in these studies, women who chose to conceive had a less severe course of MS to begin with, such that the population-level impact of pregnancy/postpartum-related disease activity on subsequent disability was underestimated.
There are many knowledge gaps in the management of MS around pregnancy, including those related to the recommendation to stop most MS disease-modifying therapies (DMTs) prior to attempting to conceive. This, combined with a rising age of motherhood that may decrease the rapidity of conception, may lead to relapse vulnerability in the period of attempting to conceive, during fertility treatments, and in early pregnancy itself. 3, 4 Women who are treated with DMTs associated with a "rebound" of MS activity upon their discontinuation may be particularly vulnerable in this period, something that was not captured in the pregnancy natural history studies published prior to the availability of higher-efficacy DMTs. 5 Breastfeeding is recommended by the American Academy of Pediatrics and the American College of Obstetrics and Gynecology, particularly for the first several months, due to benefits for infant and maternal health. 6, 7 Very little work has investigated MS DMT use in breastfeeding, and women with MS are typically advised to avoid it or to avoid DMTs until they have stopped breastfeeding.
Therefore, it is difficult to provide evidence-based treatment recommendations to women wishing to conceive. There is an urgent need to establish rigorous evidence to inform women's choices about pregnancy and breastfeeding given how common this dilemma arises in clinical practice: over 70% (and likely approaching 80%) of MS patients are women with mean diagnosis age around 30 years. Historically, some women were advised to avoid pregnancy due to concerns about MS activity, but this approach is not considered by experts to be generally advisable. 8 Observational studies can provide data to inform treatment strategies throughout pregnancy that minimize fetal risk. Multiple pregnancy registries have been established to evaluate the safety of MS DMTs during pregnancy. Some of these observational studies have yielded hard-to-interpret conclusions, such as finding a nearly fourfold increase in spontaneous abortions with natalizumab exposure among MS patients; however, the overall rates of spontaneous abortions in that cohort are still within the estimates for the general population. 9 The studies typically focus on pregnancy outcomes as the priority without substantial consideration of the MS-related health status of the mother.
Theoretically, glatiramer formulations should be safe as they are broken down at the injection site with undetectable blood levels; indeed, glatiramer has a fairly tolerable pregnancy safety rating. With the approval of monoclonal antibodies that have a therapeutic benefit that is prolonged relative to their elimination time, it may be possible to treat a woman with a safety margin of elimination of these monoclonal antibodies prior to conception and provide coverage during pregnancy, although the impact of the related immune suppression on a pregnant woman's overall health is not known.
Proper randomized clinical trials are the only way to test that these approaches are safe to the fetus and the mother while also preventing MS worsening.
Observational studies have inherent bias in that among
We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS -Yes patients who do become pregnant, those who choose to treat during pregnancy and/or breastfeeding versus those who don't or who terminate the pregnancy are probably not making these decisions at random (e.g. their MS course leading up to it or other relevant factors may have informed their decision). This "confounding" cannot be adequately adjusted for in statistical models. Through the process of randomization, clinical trials typically distribute evenly between study arms the patients with such confounding characteristics such that their impact on the results is voided. 10 Because of the vulnerable nature during pregnancy, guidelines were developed for such research by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Science Research in 1974, which were incorporated into federal regulations for research with human subjects in 1975 (45 C.F.R. § § 46.201-46.211). These guidelines provide a framework for assessing whether a pregnant women or fetus can be involved in research and are attainable in the MS population. Several conditions must be met, and MS DMTs fulfill these conditions. Briefly, the requirements are as follows: preclinical studies provide data for assessing potential risks to the pregnant women and fetuses; there is direct benefit for the woman/fetus or there is minimal risk to the fetus; any risk is the least possible (ability to attempt to minimize risk); need for informed consent of the pregnant mother; and individuals providing consent are fully informed about the reasonable foreseeable impact of the research on the fetus/neonate (in the consent). The other conditions can be avoided with proper trial design, which include the following: consent from the father if the prospect for benefit is solely to the fetus, as in the case of MS, the mother's health is also involved; assent and permission are obtained from children, limiting the studies to adults; no inducements will be offered to terminate a pregnancy; researchers will not be part of any decision as to the timing, method, or procedures to terminate a pregnancy; and researchers will not determine viability of neonates.
In summary, making MS treatment recommendations surrounding pregnancy remains one of the biggest challenges in advising women with MS who wish to conceive. Observational studies and pregnancy registries suggest that in utero exposure to some current DMTs likely confers some risks to human neonates, but the level of evidence is inadequate to fully inform the decisions that women must make with their providers. Clinical trials, which provide the best level of evidence for a given intervention, are appropriate and can be ethically conducted according to recommended guidelines, in women with MS who want to pursue pregnancy.
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